• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

COVID-19 Can Increase Risk of Psychiatric Disorders for Up to Two Years
The increased risk of depression and anxiety that patients experience after developing COVID-19 typically subsides within two months, according to astudy published yesterday inThe Lancet Psychiatry. However, patients may have an elevated risk for developing other psychiatric and neurological conditions, such as psychosis, brain fog, and seizures, for up to two years after their infections.“The results have important implications for patients and health services as it suggests new cases of neurological conditions linked to COVID-19 infection are likely to occur for a considerable time after the pandemic has subsided,” s...
Source: Psychiatr News - August 18, 2022 Category: Psychiatry Tags: adults anxiety brain fog children COVID-19 delta dementia depression older adults omicron psychotic disorder seizures The Lancet Psychiatry Source Type: research

This Under-Utilized Drug Is Actually Critical for Treatment-Resistant Depression
Many people with clinical depression have tried an array of medication and still feel sick. Maybe they’ve tried different selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). Maybe they’ve taken these antidepressants along with an antipsychotic (a common strategy to boost effectiveness). Either way, the lack of improvement can make individuals feel even more hopeless and fear the darkness will never lift. If this sounds all-too familiar, you’re definitely not alone. In fact, up to 30 percent of people with depression don’t respond to the first few antidepressants ...
Source: Psych Central - November 27, 2019 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Antidepressants Depression Disorders ECT General Medications Treatment Atypical Depression difficult to treat depression Managing Depression MAOIs medication for depression Monoamine Oxidase Inhibitors Severe Depression Treatin Source Type: news

Cardioprotective Activity of Agaricus bisporus Against Isoproterenol- Induced Myocardial Infarction in Laboratory Animals
Conclusion: It can be an outcome that EEAB possessed cardioprotective activity against experimental and clinical studies of ISO-induced myocardial infarction in rats.
Source: Current Nutrition and Food Science - June 28, 2019 Category: Nutrition Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research